Drospirenone
| Drospirenone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 366.50 g/mol [1] |
| Melting point | 196-200 [1] |
| Boiling point | 552.2 [1] |
| Solubility | 2.25e-03 g/L [1] |
| Predicted LogP | 3.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C24H30O3 |
| IUPAC name | (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione |
| SMILES | C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C |
| InChI | InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 |
| InChIKey | METQSPRSQINEEU-HXCATZOESA-N |
| CAS number | 67392-87-4 |
| UNII | N295J34A25 |
| PubChem CID | 68873 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 25–33 hours |
| Metabolism | Liver (mostly CYP450-independent (reduction, sulfation, and cleavage of lactone ring), some CYP3A4 contribution)[3][4][5] |
| Excretion | Urine, feces |
| Routes of administration | By mouth |
Drospirenone (also known as Dehydrospirorenone, Dihydrospirorenone, Drospirenona, 1,2-Dihydrospirorenone, DRSP, Drospirenonum, Zk 30595, Slynd, Zk-30595 or Zk30595).
Chemistry
Stereochemistry []
Drospirenone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Drospirenone matches Lipinski's rule of five.Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- sex hormones and modulators of the genital system (G03)
- hormonal contraceptives for systemic use (G03A)
- progestogens (G03AC)
- drospirenone (G03AC10)
- (G03FA17)
MeSH Classification
- mineralocorticoid receptor antagonists (M0570017)
Mechanism of action []
Drospirenone and ethinyl estradiol in combination suppress the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH), preventing ovulation. Other changes induced by this drug which may aid in the prevention of pregnancy include alterations in cervical mucus consistency, hindering sperm movement, and lowering the chance of embryo implantation. Drospirenone is an analog of the diuretic spironolactone, which exerts anti-mineralocorticoid activity, blocking aldosterone receptors, which increases sodium and water excretion. Studies in animals have demonstrated that drospirenone administration leads to antiandrogenic activity. This activity helps to oppose the effects of naturally occurring androgens, inhibiting the binding of dihydrotestosterone (DHT) to its receptor, and preventing androgen synthesis in the ovaries, helping to treat acne and hirsutism. Drospirenone may also decrease the level of edema in sebaceous follicle during the second half of the menstrual cycle, when acne often appears. [1]
Interactions []
Medical side effects []
28 side effects listed on drug labels in SIDER 4.1 (drospirenone).
- Mental disorder
- Breast disorder
- Cerebral infarction
- Depression
- Embolism
- Thromboembolic event
- Erythema multiforme
- Gastrointestinal disorder
- Haemorrhage
- Haemoglobin
- Infarction
- Breast pain
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Nervous system disorder
- Cerebrovascular accident
- Thrombosis
- Uterine haemorrhage
- Angiopathy
- Mood swings
- Affect lability
- Migraine
- Skin disorder
- Venous occlusion
- Vascular occlusion
- Embolism venous
- Loss of libido
Legal status []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 68873, Drospirenone. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/68873
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Drospirenone. UNII: N295J34A25. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/N295J34A25
Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. April 2004; 69(4):271–278. PMID 15033400. https://doi.org/10.1016/j.contraception.2003.11.003
Bachmann G, Kopacz S. Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient Preference and Adherence. November 2009; 3:259–264. PMID 19936169. https://doi.org/10.2147/PPA.S3901
Wiesinger H, Berse M, Klein S, Gschwend S, Höchel J, Zollmann FS, Schütt B. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. British Journal of Clinical Pharmacology. December 2015; 80(6):1399–1410. PMID 26271371. https://doi.org/10.1111/bcp.12745
Lucinda (Lupin Australia Pty Limited). Therapeutic Goods Administration (TGA). 14 January 2025. https://www.tga.gov.au/resources/prescription-medicines-registrations/lucinda-lupin-australia-pty-limited
Health product highlights 2021: Annexes of products approved in 2021. Health Canada. 3 August 2022. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:01:31 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:01:27 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:01:27 |
| gsrs | ok | 2026-11-20 19:01:27 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015467) | 2026-11-20 19:01:27 |
| kegg | ok | 2026-11-20 19:01:29 |
| pubchem | ok | 2026-11-20 19:01:26 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:01:27 | |
| sider | ok | 2026-11-20 19:01:27 |
| structure | ok | 2026-11-20 19:01:27 |
| wikipedia | ok | 2026-11-20 19:01:27 |